Timeline now= NTM - US 2018 / EU 2016 CF ? .........if approved.
Arikayce will not enter the CF market in the U.S. There will be sales outside of the US but relatively low in numbers..
As Wainwright comments- " Arikayce’s value remains tied to the US NTM indication" .
Problems in Europe applications are possible., the co has been vague ( double filing ? EMMA "push" agreed to by the EU? Insmed has positive catalysts to be sure with strong institutional support (investing hoping for a buyout is poor investing) but is possible given a large pharma could make the promise of liposomal technology far sooner with resources Insmed does not have. .Good Luck